FAQs & Video Library

Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible patients with licensed healthcare providers for personalized medical weight-management care.

Yes. Bodi Envi is a LegitScript-certified telehealth platform. Licensed healthcare providers make clinical evaluation and prescribing decisions. When treatment is prescribed, fulfillment is handled by VialsRx, a 503A licensed pharmacy located at 16402 FM 2920, Building D, Tomball, TX 77377. Phone: 346-781-8772.

Yes. Bodi Envi is LegitScript certified.

No. Bodi Envi is a telehealth platform. Bodi Envi uses Wasef Health, PC as the clinical provider organization, and licensed physicians and nurse practitioners independently review patient information and make all clinical decisions.

No. Bodi Envi is not a pharmacy. When medication is prescribed, the prescription is sent to VialsRx, a 503A licensed pharmacy located at 16402 FM 2920, Building D, Tomball, TX 77377, for dispensing and fulfillment. Phone: 346-781-8772.

No. Bodi Envi does not manufacture or compound medication.

Licensed healthcare providers provide clinical evaluation and care. Wasef Health, PC provides clinical services for Bodi Envi programs. Wasef Health, PC, c/o Michael Wasef, MD, 5260 78th Ave N, PO Box 1697, Pinellas Park, FL 33780. Email: contact@wasef-health.com.

Michael Wasef, MD serves as Medical Director for applicable Bodi Envi clinical programs through Wasef Health, PC. Dr. Wasef is a board-certified internal medicine physician.

Bodi Envi is based in Tampa, Florida and provides telehealth services to eligible patients in all 50 states.

Bodi Envi facilitates care through telehealth only.

Patients begin with an online health assessment. A licensed healthcare provider reviews the patient's medical information and determines whether treatment is appropriate. When prescribed, medication is sent to VialsRx, a licensed 503A pharmacy located at 16402 FM 2920, Building D, Tomball, TX 77377, for fulfillment. Phone: 346-781-8772.

No. Completing an assessment or paying for a program does not guarantee a prescription. A licensed healthcare provider determines whether prescription treatment is medically appropriate. If you do not qualify, a refund will be issued according to the applicable policy.

Patients receive clinical evaluation by a licensed healthcare provider and can communicate with their care team according to the applicable program's telehealth process.

Bodi Envi patients can communicate with their care team through the patient portal according to the services included in their program.

Yes, current patients receive ongoing medical support and access to the provider team associated with their treatment program.

Yes. A licensed healthcare provider may adjust treatment based on medical history, treatment response, tolerability, and independent clinical judgment. Patients can request changes through support or their care team.

No. Individual responses to treatment vary, and no specific amount of weight loss can be guaranteed.

Medical weight management is a primary Bodi Envi service. Other wellness services are available.

Yes. Licensed healthcare providers evaluate individual medical information and determine an appropriate treatment plan based on each patient's needs.

Personalized compounded semaglutide is a compounded GLP-1 receptor agonist program that may be considered by a licensed healthcare provider for eligible patients. FDA-approved semaglutide products exist for specific indications. Personalized compounded semaglutide is a different category of product and is not FDA-approved. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards for sterile compounding.

Bodi Envi offers access to medical weight-management programs that may include personalized compounded semaglutide when a licensed healthcare provider determines it is appropriate.

No. Personalized compounded semaglutide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness, or quality. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding and required to follow United States Pharmacopeia standards.

No. Bodi Envi does not represent personalized compounded semaglutide as equivalent to FDA-approved semaglutide products.

Personalized compounded semaglutide activates GLP-1 receptors involved in appetite, food intake, and glucose regulation. It may help lower blood sugar levels, reduce food cravings, and support appetite control. Treatment effects and individual responses vary.

Medication is administered by subcutaneous injection with a small insulin needle. Patients should follow the exact instructions provided by their healthcare provider and dispensing pharmacy.

It is commonly prescribed on a weekly schedule or bi-weekly micro-dosing schedule, but patients must follow their individual prescription and provider instructions. A provider may also prescribe split dosing on an individual basis.

Gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort can occur. Patients should discuss potential adverse effects and serious warnings with their healthcare provider.

Personalized compounded semaglutide is not appropriate for everyone. A licensed healthcare provider should review medical history, medications, contraindications, warnings, and individual risk factors before treatment.

Results vary considerably. Your provider can discuss treatment response, progress, and whether a treatment plan remains appropriate for you.

Personalized compounded tirzepatide has activity at GIP and GLP-1 receptors involved in appetite and metabolic regulation. It may help control appetite, reduce blood sugar spikes, and reduce food cravings, though effects vary by individual. FDA-approved tirzepatide products exist for specific indications. Personalized compounded tirzepatide is not FDA-approved. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding and required to follow United States Pharmacopeia standards.

Yes. Bodi Envi offers medical weight-management programs that may include personalized compounded tirzepatide when a licensed healthcare provider determines it is appropriate.

No. Personalized compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness, or quality. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding and required to follow United States Pharmacopeia standards.

No. Bodi Envi does not represent personalized compounded tirzepatide as equivalent to FDA-approved tirzepatide products, including Zepbound or Mounjaro.

Personalized compounded tirzepatide activates GIP and GLP-1 receptors involved in appetite and metabolic regulation. It may help reduce blood sugar spikes, control appetite, and reduce cravings. Treatment effects and individual responses vary.

It is commonly prescribed on a weekly or bi-weekly micro-dosing schedule, but patients must follow the individual instructions provided by their healthcare provider and dispensing pharmacy. A provider may also prescribe split dosing on an individual basis.

Common adverse effects can include nausea, diarrhea, vomiting, constipation, decreased appetite, and abdominal symptoms. Other side effects can occur. Patients should discuss risks and warnings with their healthcare provider.

Personalized compounded tirzepatide is not appropriate for everyone. Eligibility is determined by a licensed healthcare provider after reviewing medical history, medications, contraindications, and individual risk factors.

Results vary considerably. Your provider can discuss treatment response, progress, and whether a treatment plan remains appropriate for you.

Neither option is automatically better for every patient. Tirzepatide has activity at two receptor pathways (GIP and GLP-1) where semaglutide has activity at one, but the medications have different pharmacology overall, and a licensed healthcare provider determines what may be appropriate based on individual circumstances.

A personalized compounded medication is prepared by a compounding pharmacy for an individual patient prescription or other circumstances permitted under applicable law. Compounded drugs are not FDA-approved. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding and required to follow United States Pharmacopeia standards.

No. Personalized compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding and required to follow United States Pharmacopeia standards.

No. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed in the same way it reviews FDA-approved drugs. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding and required to follow United States Pharmacopeia standards. Medication is required to be tested in accordance with sterile compounding regulations prior to patient release.

No. A compounded drug should not be described as a generic version of an FDA-approved drug.

No. Compounded GLP-1 medications are not FDA-approved and should not be represented as equivalent to FDA-approved products.

A licensed healthcare provider may determine that a personalized compounded medication is appropriate for an individual patient when permitted under applicable law and based on that patient's medical needs, including needs a mass-produced product does not address.

No. Bodi Envi does not manufacture or compound medications. Bodi Envi is a telehealth platform that connects eligible patients with licensed healthcare providers for clinical evaluation.

Bodi Envi partners with VialsRx, a 503A licensed pharmacy, located at 16402 FM 2920, Building D, Tomball, TX 77377. Phone: 346-781-8772.

No. VialsRx is a separate pharmacy organization and is not Bodi Envi.

Medication is dispensed and shipped by VialsRx, a licensed 503A pharmacy, located at 16402 FM 2920, Building D, Tomball, TX 77377. Phone: 346-781-8772.

No. Bodi Envi is the telehealth platform. Prescription fulfillment and medication shipping are handled by VialsRx, a licensed 503A pharmacy.

Shipping times vary based on prescription processing, pharmacy operations, patient location, holidays, and other factors. Refer to current shipping information or contact support for help with a specific order.

The dispensing pharmacy is identified on medication packaging and prescription documentation. Patients may also contact the care or support team with fulfillment questions.

As of September 2026, personalized compounded semaglutide plans range from $125 to $155 per month and personalized compounded tirzepatide plans range from $175 to $229 per month, depending on the plan selected. Because pricing can change, review the current treatment page before enrolling or email info@bodienvi.com with specific questions.

No, pricing does not increase for dose changes.

Yes, expedited shipping is included.

The licensed provider evaluation and medication are included.

Bodi Envi offers applicable self-pay programs that do not require health insurance.

Eligible healthcare expenses may qualify for HSA or FSA reimbursement depending on the expense and your plan. Verify eligibility with your plan administrator. Bodi Envi can provide an itemized superbill for potential reimbursement; for a superbill request, email info@bodienvi.com.

No, Bodi Envi does not have any hidden fees.

Yes. You can request cancellation through your patient portal, by emailing info@bodienvi.com, or by calling 1-855-348-2630.

Personalized compounded GLP-1 medications are not FDA-approved and do not undergo FDA premarket review, though compounding pharmacies are regulated by the board of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards. Medication is required to be tested for strength and sterility in accordance with sterile compounding regulations prior to patient release. A licensed healthcare provider reviews individual medical information and can discuss potential benefits, risks, warnings, and alternatives.

Contact your licensed healthcare provider if you experience side effects. Do not independently change treatment. For a medical emergency, call 911 or seek immediate emergency care.

Nausea can occur with GLP-1 treatment. For eligible patients, Bodi Envi may offer ondansetron to help manage nausea; reach out to customer service or your provider if you would like nausea medication added to your program. Discuss persistent, severe, or concerning symptoms with your healthcare provider rather than independently changing treatment. Your provider can discuss appropriate care options based on your clinical situation.

Yes. A licensed healthcare provider may lower your dose, or move to split or alternative dosing, based on your symptoms, medical history, tolerability, and independent clinical judgment.

Long-term weight-management plans are individualized. A healthcare provider can discuss maintenance, lifestyle strategies, micro-dosing maintenance plans, and whether other treatment changes may be appropriate.

Weight regain can occur after weight-management treatment is discontinued. Long-term outcomes vary: some patients discontinue without regaining, particularly alongside sustained lifestyle changes, while others may need ongoing maintenance dosing. Patients should discuss maintenance planning with their healthcare provider.

Medical weight-management treatment is generally used alongside appropriate nutrition, physical activity, and behavioral or lifestyle strategies based on individual circumstances.

Start with Bodi Envi's health assessment. A licensed healthcare provider can evaluate your health information and determine whether an available treatment option may be appropriate. Completing an assessment does not guarantee a prescription.